Ceftobiprole medocaril

Jump to: navigation, search
Ceftobiprole medocaril
Ceftobiprole Wiki Str.png
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration
Intravenous
ATC code
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC20H22N8O6S2
Molar mass534.568 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Ceftobiprole medocaril

Articles

Most recent articles on Ceftobiprole medocaril

Most cited articles on Ceftobiprole medocaril

Review articles on Ceftobiprole medocaril

Articles on Ceftobiprole medocaril in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Ceftobiprole medocaril

Images of Ceftobiprole medocaril

Photos of Ceftobiprole medocaril

Podcasts & MP3s on Ceftobiprole medocaril

Videos on Ceftobiprole medocaril

Evidence Based Medicine

Cochrane Collaboration on Ceftobiprole medocaril

Bandolier on Ceftobiprole medocaril

TRIP on Ceftobiprole medocaril

Clinical Trials

Ongoing Trials on Ceftobiprole medocaril at Clinical Trials.gov

Trial results on Ceftobiprole medocaril

Clinical Trials on Ceftobiprole medocaril at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Ceftobiprole medocaril

NICE Guidance on Ceftobiprole medocaril

NHS PRODIGY Guidance

FDA on Ceftobiprole medocaril

CDC on Ceftobiprole medocaril

Books

Books on Ceftobiprole medocaril

News

Ceftobiprole medocaril in the news

Be alerted to news on Ceftobiprole medocaril

News trends on Ceftobiprole medocaril

Commentary

Blogs on Ceftobiprole medocaril

Definitions

Definitions of Ceftobiprole medocaril

Patient Resources / Community

Patient resources on Ceftobiprole medocaril

Discussion groups on Ceftobiprole medocaril

Patient Handouts on Ceftobiprole medocaril

Directions to Hospitals Treating Ceftobiprole medocaril

Risk calculators and risk factors for Ceftobiprole medocaril

Healthcare Provider Resources

Symptoms of Ceftobiprole medocaril

Causes & Risk Factors for Ceftobiprole medocaril

Diagnostic studies for Ceftobiprole medocaril

Treatment of Ceftobiprole medocaril

Continuing Medical Education (CME)

CME Programs on Ceftobiprole medocaril

International

Ceftobiprole medocaril en Espanol

Ceftobiprole medocaril en Francais

Business

Ceftobiprole medocaril in the Marketplace

Patents on Ceftobiprole medocaril

Experimental / Informatics

List of terms related to Ceftobiprole medocaril

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Ceftobiprole (Zeftera/Zevtera) is a fifth-generation[2] cephalosporin antibiotic with activity against methicillin-resistant Staphylococcus aureus, penicillin-resistant Streptococcus pneumoniae, Pseudomonas aeruginosa, and enterococci.[3][4][5] It was discovered by Basilea Pharmaceutica[6] and was developed by Johnson & Johnson Pharmaceutical Research and Development.[7] It has been shown to be statistically noninferior to the combination of vancomycin and ceftazidime for the treatment of skin and soft tissue infections.[8]

It has been described as a fifth-generation cephalosporin,[9][10] though acceptance for this terminology is not universal.

Pharmacology

Like other cephalosporins, ceftobiprole inhibits bacterial growth by blocking penicillin-binding protein, a key enzyme involved in cell wall synthesis. Ceftobiprole inhibits the 2a penicillin-binding protein (PBP) of methicillin-resistant Staphylococcus aureus and the 2x PBP of Streptococcus pneumoniae,[4] as well as the classic PBP-2 of MSSA. Ceftobiprole is resistant to staphylococcal β-lactamase.[6]

Mode of administration

Ceftobiprole is given intravenously; it cannot be given by mouth.

Regulatory approvals

Ceftobiprole has been approved for use in Canada, Switzerland, and the European Union.[11] It is under review by regulatory authorities in the United States, Australia, Russia, and South Africa.[12] In November 2008, the US FDA declined to approve ceftobiprole, citing data integrity concerns with two of the supporting studies,[13] and prompting Basilea to sue Johnson & Johnson for breach of license agreement on February 2009.[14]

Synonyms

  • RO0639141-000[6]
  • BAL9141[15]
  • Ceftobiprole medocaril

References

  1. WHO International Working Group for Drug Statistics Methodology (August 27, 2008). "ATC/DDD Classification (FINAL): New ATC 5th level codes". WHO Collaborating Centre for Drug Statistics Methodology. Retrieved 2008-09-05.
  2. Kollef MH (December 2009). "New antimicrobial agents for methicillin-resistant Staphylococcus aureus". Crit Care Resusc. 11 (4): 282–6. PMID 20001879.
  3. Yun HC, Ellis MW, Jorgensen JH (2007). "Activity of ceftobiprole against community-associated methicillin-resistant Staphylococcus aureus isolates recently recovered from US military trainees". Diagnostic Microbiology and Infectious Disease. 59 (4): 463–6. doi:10.1016/j.diagmicrobio.2007.06.023. PMID 17911001.
  4. 4.0 4.1 Widmer A (2008). "Ceftobiprole: A new option for treatment of skin and soft-tissue infections due to methicillin-resistant Staphylococcus aureus". Clin Infect Dis. 46 (5): 656–8. doi:10.1086/526528. PMID 18225983.
  5. Noel GJ, Bush K, Bagchi P, Ianus J, Strauss RS (2008). "A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections". Clin Infect Dis. 46 (5): 647–55. doi:10.1086/526527. PMID 18225981.
  6. 6.0 6.1 6.2 Hebeisen P, Heinze-Krauss I, Angehrn P; et al. (2001). "In vitro and in vivo properties of Ro63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci". Antimicrob Agents Chemother. 45 (3): 825–36. doi:10.1128/AAC.45.3.825-836.2001. PMC 90381. PMID 11181368.
  7. Basilea.com
  8. Noel, Gary J.; Karen Bush; Partha Bagchi; Juliana Ianus; Richard S. Strauss (2008). "A Randomized, Double-Blind Trial Comparing Ceftobiprole Medocaril with Vancomycin plus Ceftazidime for the Treatment of Patients with Complicated Skin and Skin-Structure Infections". Clin Infect Dis. 46 (5): 647-655. doi:10.1086/526527. PMID 18225981. |access-date= requires |url= (help)
  9. Widmer AF (March 2008). "Ceftobiprole: a new option for treatment of skin and soft-tissue infections due to methicillin-resistant Staphylococcus aureus". Clin. Infect. Dis. 46 (5): 656–8. doi:10.1086/526528. PMID 18225983.
  10. Kosinski MA, Joseph WS (July 2007). "Update on the treatment of diabetic foot infections". Clin Podiatr Med Surg. 24 (3): 383–96, vii. doi:10.1016/j.cpm.2007.03.009. PMID 17613382.
  11. Basilea antibiotic to treat pneumonia wins European backing. Reuters, ZURICH | Wed Oct 23, 2013.
  12. Basilea superbug drug approved in Canada, Reuters News, June 30, 2008
  13. http://www.dancewithshadows.com/pillscribe/ceftobiprole-antibiotic-to-fight-tougher-bacterial-infections-fails-to-win-approval-in-us/
  14. "Basilea Pharmaceutica Ltd. announces that the U.S. Food and Drug Administration (FDA) issued to the sponsor, Johnson & Johnson Pharmaceutical Research and Development, L.L.C. (Johnson & Johnson PRD), a Complete Response Letter on ceftobiprole for the treatment of complicated skin and skin structure infections (cSSSI" (Press release). Basilea Pharmaceutica. 2009-07-02. Retrieved February 2, 2010.
  15. Jones RN, Deshpande LM, Mutnick AH, Biedenbach DJ (2002). "In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci". J Antimicrob Chemother. 50 (6): 915–932. doi:10.1093/jac/dkf249. PMID 12461013.

Linked-in.jpg